(HealthDay News) — Overall, cancer detection in the United States recovered meaningfully in 2021 following substantial disruptions in 2020, according to a study published online in JAMA Network Open.

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

Gilead has made the decision to withdraw the accelerated approval of Trodelvy (sacituzumab govitecan) for advanced urothelial cancer in the United States.

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...